Skip to main content

Table 1 Study participant characteristics

From: Fatigue severity in anti-nuclear antibody-positive individuals does not correlate with pro-inflammatory cytokine levels or predict imminent progression to symptomatic disease

 

HC (n = 29)

ANS (n = 46)

UCTD (n = 29)

SARD (n = 42)

SjD (n = 11)

SLE (n = 11)

SSc (n = 18)

MCTD/DM (n = 2)

Age, mean ± SD

29.3 ± 9.8

47.0 ± 14.0

48.3 ± 16.5

47.4 ± 14.9

47.7 ± 14.4

35.7 ± 12.3

54.7 ± 13.3

44 ± 1.4

Female sex, n (%)

25 (86.2)

44 (95.7)

27 (93.1)

40 (95.2)

10 (90.9)

11 (100)

16 (88.9)

2 (100)

Ethnicity, n (%)

 Caucasian

12 (41.4)

26 (56.5)

20 (69.0)

26 (61.9)

7 (63.6)

6 (54.5)

12 (66.7)

1 (50)

 Asian

0 (0)

3 (6.5)

5 (17.2)

2 (4.8)

1 (9.1)

0 (0)

1 (5.6)

0 (0)

 South Asian

5 (17.2)

5 (10.9)

2 (6.9)

5 (11.9)

2 (18.2)

1 (9.1)

2 (11.1)

0 (0)

 Hispanic

7 (24.1)

2 (4.3)

1 (3.4)

4 (9.5)

0 (0)

1 (9.1)

3 (16.7)

0 (0)

 African Canadian

1 (3.4)

7 (15.2)

0 (0)

1 (2.4)

0 (0)

1 (9.1)

0 (0)

0 (0)

 Filipino

1 (3.4)

1 (2.2)

0 (0)

2 (4.8)

0 (0)

1 (9.1)

0 (0)

1 (50)

 Mixed

3 (10.3)

2 (4.3)

1 (3.4)

2 (4.8)

1 (9.1)

1 (9.1)

0 (0)

0 (0)

Fibromyalgia, n (%)

0 (0)

17 (37.0)

13 (44.8)

12 (28.6)

2 (18.2)

3 (27.3)

6 (33.3)

1 (50.0)

Anemia, n (%)

0 (0)

4 (8.7)

0 (0)

2 (4.8)

0 (0)

1 (9.1)

1 (5.6)

0 (0)

Hypothyroidism, n (%)

0 (0)

4 (8.7)

0 (0)

2 (4.8)

1 (9.1)

0 (0)

1 (5.6)

0 (0)

Depression, n (%)

0 (0)

3 (6.5)

2 (6.9)

2 (4.8)

1 (9.1)

0 (0)

1 (5.6)

0 (0)

On anti-malarials, n (%)

0 (0)

4 (8.7)

6 (20.7)

4 (9.5)

1 (9.1)

2 (18.2)

1 (5.6)

0 (0)

Specific antibodies, n (%)

 dsDNA

0 (0)

4 (8.7)

2 (6.9)

7 (16.7)

2 (18.2)

3 (27.3)

2 (11.1)

0 (0)

 Ro

0 (0)

11 (23.9)

9 (31.0)

19 (45.2)

11 (100)

5 (45.5)

3 (16.7)

0 (0)

 La

0 (0)

4 (8.7)

2 (6.9)

8 (19.0)

7 (63.6)

1 (9.1)

0 (0)

0 (0)

 Sm

0 (0)

2 (4.3)

1 (3.4)

4 (9.5)

0 (0)

3 (27.3)

0 (0)

1 (50.0)

 Sm/RNP

0 (0)

3 (6.5)

2 (6.9)

6 (14.3)

0 (0)

4 (36.4)

1 (5.6)

1 (50.0)

 RNP

0 (0)

6 (13.0)

3 (10.3)

8 (19.0)

2 (18.2)

4 (36.4)

1 (5.6)

1 (50.0)

 Scl-70

0 (0)

1 (2.2)

1 (3.4)

8 (19.0)

1 (9.1)

2 (18.2)

5 (27.8)

0 (0)

 Jo-1

0 (0)

0 (0)

0 (0)

0 (0)

0 (0)

0 (0)

0 (0)

0 (0)

 Centromere

0 (0)

1 (2.2)

3 (10.3)

15 (35.7)

0 (0)

1 (9.1)

13 (72.2)

1 (50.0)

 Chromatin

0 (0)

5 (10.9)

2 (6.9)

7 (16.7)

1 (9.1)

5 (45.5)

0 (0)

1 (50.0)

  1. Abbreviations: HC healthy controls, ANS asymptomatic ANA+, UCTD undifferentiated connective tissue disease, SARD systemic autoimmune rheumatic disease, SjD Sjögren’s disease, SLE systemic lupus erythematosus, SSc systemic sclerosis, MCTD mixed connective tissue disease, DM dermatomyositis, dsDNA double-stranded DNA, Sm Smith, RNP ribonuclear protein
Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us